SEC Company Response from PALVELLA THERAPEUTICS, INC. (PVLA) (CIK 0001583648) (PVLA) — Aug 21, 2018
PALVELLA THERAPEUTICS, INC. (PVLA) (CIK 0001583648)
Date: Aug. 21, 2018 · CIK: 0001583648 · Accession: 0001583648-18-000056
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-226725
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Mr. Jonathan Burr Registration Statement on Form S-3 Filed August 9, 2018 File No. 333-226725 Acceleration Request
Dear Mr. Burr:
With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby requests, on behalf of Pieris Pharmaceuticals, Inc. (the “Company”), that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to Friday, August 24, 2018, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please contact Marc D. Mantell, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 348-3058, with any comments or questions regarding the Registration Statement.
Very truly yours,
PIERIS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm Document PIERIS PHARMACEUTICALS, INC. 255 State Street, 9th Floor Boston, MA 02109 August 21, 2018 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Jonathan Burr RE: Pieris Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed August 9, 2018 File No. 333-226725 Acceleration Request Dear Mr. Burr: With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby requests, on behalf of Pieris Pharmaceuticals, Inc. (the “Company”), that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to Friday, August 24, 2018, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please contact Marc D. Mantell, Esq. of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (617) 348-3058, with any comments or questions regarding the Registration Statement. Very truly yours, PIERIS PHARMACEUTICALS, INC. /s/ Stephen S. Yoder Stephen S. Yoder President and Chief Executive Officer cc: Ahmed Mousa, Esq., Pieris Pharmaceuticals, Inc. Marc D. Mantell, Esq., Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.